Meeting
2022 ASCO Annual Meeting
Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study.
Authors
Angela Damato
Medical Oncology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
Angela Damato , Angela Damato , Carlo Aschele , Fortunato Ciardiello , Evaristo Maiello , Salvatore Siena , Valter Torri , Virginia Dolcini , Erika Gervasi , Ilenia La Grotteria , Irene De Simone , Nicola Normanno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04776655
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3636)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3636
Abstract #
TPS3636
Poster Bd #
426a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio
Poster
2023 ASCO Annual Meeting
Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).
First Author: Nicola Normanno
Poster
2021 ASCO Annual Meeting
Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.
First Author: Jonathan Poh
Poster
2019 Gastrointestinal Cancers Symposium
Molecular analysis of advanced colorectal cancer in an ethnically diverse patient population at a single institution.
First Author: Nadia Ashai